The benefit of this diagnostic radiopharmaceutical is its potential to diagnose prostate cancer during primary staging of patients at high risk and in the staging of patients with a suspected recurrence
Findings from the prespecified final overall survival analysis of the PAOLA-1/ENGOT-ov25 study
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
Findings from the MAINTAIN study
Findings from the CATCH-IT Consortium study